Drug Res (Stuttg) 2016; 66(03): 165-168
DOI: 10.1055/s-0035-1564101
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial

S. Karami
1   Food & Drug Control Laburatory, Shiraz University of Medical Sciences, Shiraz, Iran
,
G. Dehghanzadeh
1   Food & Drug Control Laburatory, Shiraz University of Medical Sciences, Shiraz, Iran
2   Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
,
M. Haghighat
3   Department of Pediatric, Shiraz University of Medical Sciences, Shiraz, Iran
,
R. Mirzaei
1   Food & Drug Control Laburatory, Shiraz University of Medical Sciences, Shiraz, Iran
,
H. R. Rahimi
4   Department of Toxicology & Pharmacology, School of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran
5   Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 14. März 2015

accepted 20. August 2015

Publikationsdatum:
23. September 2015 (online)

Abstract

Although, omeprazole is widely used for treatment of gastric acid-mediated disorders. However, its pharmacokinetic and chemical instability does not allow simple aqueous dosage form formulation synthesis for therapy of, especially child, these patients. The aim of this study was at first preparation of suspension dosage form omeprazole and second to compare the blood levels of 2 oral formulations/dosage forms of suspension & granule by high performance liquid chromatography (HPLC). The omeprazole suspension was prepared; in this regard omeprazole powder was added to 8.4% sodium bicarbonate to make final concentration 2 mg/ml omeprazole. After that a randomized, parallel pilot trial study was performed in 34 pediatric patients with acid peptic disorder who considered usage omeprazole. Selected patients were received suspension and granule, respectively. After oral administration, blood samples were collected and analyzed for omeprazole levels using validated HPLC method. The mean omeprazole blood concentration before usage the next dose, (trough level) were 0.12±0.08 µg/ml and 0.18±0.15 µg/ml for granule and suspension groups, respectively and mean blood level after dosing (C2 peak level) were 0.68±0.61 µg/ml and 0.86±0.76 µg/ml for granule and suspension groups, respectively. No significant changes were observed in comparison 2 dosage forms 2 h before (P=0.52) and after (P=0.56) the last dose. These results demonstrate that omeprazole suspension is a suitable substitute for granule in pediatrics.

 
  • References

  • 1 Martindale: the complete drug reference. 35th ed. London: Pharmaceutical Press; 2007
  • 2 Zarghi A, Foroutan SM, Shafaati A et al. HPLC determination of omeprazole in human plasma using a monolithic column. Arzneimittel-Forschung 2006; 56: 382-386
  • 3 Vaz-da-Silva M, Loureiro AI, Nunes T et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clinical drug investigation 2005; 25: 391-399
  • 4 Shimizu M, Uno T, Niioka T et al. Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. Journal of chromatography B, Analytical technologies in the biomedical and life sciences 2006; 832: 241-248
  • 5 Hofmann U, Schwab M, Treiber G et al. Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography B 2006; 831: 85-90
  • 6 Murakami FS, Lang KL, Mendes C et al. Physico-chemical solid-state characterization of omeprazole sodium: thermal, spectroscopic and crystallinity studies. Journal of pharmaceutical and biomedical analysis 2009; 49: 72-80
  • 7 Education MoHaM. Iranian National Formulary. Tehran: Shahid Beheshti University of Medical Sciences; 2010
  • 8 Cristina I, Mirela M AdinaP et al. Validation of HPLC-UV method for analysis of omeprazole in presence of its metabolites in human plasma. FARMACIA 2008; 3: 254-260
  • 9 Wang J, Wang Y, Fawcett JP et al. Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry. J Pharm Biomed Anal 2005; 39: 631-635
  • 10 Zimmer D. New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR. Bioanalysis 2014; 6: 13-19
  • 11 Rahimi HR, Rasouli M, Jamshidzadeh A et al. New immunological investigations on Helicobacter pylori-induced gastric ulcer in patients. Microbiology Immunology 2013; 57: 455-462
  • 12 Rahimi HR, Arastoo M, Shiri M. Punica granatum is more effective to prevent gastric disorders induced by helicobacter pylori or any other stimulator in humans. Asian Journal of Plant Sciences 2011; 10: 380-392
  • 13 Jamalifar H, Rahimi H, Samadi N et al. Antimicrobial activity of different Lactobacillus species against multi-drug resistant clinical isolates of Pseudomonas aeruginosa. Iranian Journal of Microbiology 2011; 3: 21-25
  • 14 Solouki M, Marashian SM, Kouchak M et al. Comparison between the Preventive Effects of Ranitidine and Omeprazole on Upper Gastrointestinal Bleeding among ICU Patients. Tanaffos 2009; 8: 37-42
  • 15 Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. The Journal of trauma 1998; 44: 527-533